Press Releases IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Market Closed - OTC Markets Other stock markets 12:48:56 14/05/2024 am IST			5-day change	1st Jan Change
0.1648 ^USD	+3.65%		-13.26%	+19.33%

08/04	Intelgenx Announces First Parkinson?S Disease Patients Dosed with Montelukast Versafilm® in Phase 2 ?Montpark? Clinical Trial	CI
05/04	IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IntelGenx Announces Voting Results on Election of Directors	08/05	GL
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial	08/04	GL
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	08/04	AQ
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA	05/04	GL
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results	21/03	GL
IntelGenx Technologies : 25 10.42pm MOCK-UP with special characters / * $ % + ` ' ' `	15/03	PU
IntelGenx Technologies : 26 10.45pm MOCK-UP with special characters / * $ % + ` ' ' `	15/03	PU
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow	15/03	GL
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03	GL
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences	11/03	AQ
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering	20/02	GL
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform	05/02	GL
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform	05/02	AQ
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®	18/12	GL
IntelGenx Announces New Animal Health Partnership; Enters into Development and License Agreements for VetaFilm®	18/12	AQ
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000	05/12	GL
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000	05/12	AQ
IntelGenx Announces Changes to its Board of Directors	04/12	GL
IntelGenx Announces Changes to its Board of Directors	04/12	AQ
IntelGenx Announces Shareholder Approval of Financing Transactions	29/11	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases IntelGenx Technologies Corp.

Equities

IGXT

US45822R1014

Press Releases

Filters